Mechanisms determining characteristic age-of-onset for neurological diseases are largely unknown. Normal brain aging associates with robust and progressive transcriptome changes ("molecular aging"), but the intersection with disease pathways is mostly uncharacterized. Here, using cross-cohort microarray analysis of four human brain areas, we show that neurological disease pathways largely overlap with molecular aging and that subjects carrying a newly-characterized low-expressing polymorphism in a putative longevity gene (Sirtuin5; SIRT5 prom2 ) have older brain molecular ages. Specifically, molecular aging was remarkably conserved across cohorts and brain areas, and included numerous developmental and transcription-regulator genes. Neurological disease-associated genes were highly overrepresented within age-related genes and changed almost unanimously in pro-disease directions, together suggesting an underlying genetic "program" of aging that progressively promotes disease. To begin testing this putative pathway, we developed and used an age-biosignature to assess five candidate longevity gene polymorphisms' association with molecular aging rates. Most robustly, aging was accelerated in cingulate, but not amygdala, of subjects carrying a SIRT5 promoter polymorphism (+9 years, p=0.004), in concordance with cingulate-specific decreased SIRT5 expression. This effect was driven by a set of core transcripts (+24 years, p=0.0004), many of which were mitochondrial, including Parkinson's disease genes, PINK-1 and DJ-1/PARK7, hence suggesting that SIRT5 prom2 may represent a risk factor for mitochondrial dysfunction-related diseases, including Parkinson's, through accelerated molecular aging of disease-related genes. Based on these results we speculate that a "common mechanism" may underlie age-of-onset across several neurological diseases. Confirming this pathway and its regulation by common genetic variants would provide new strategies for predicting, delaying, and treating neurological diseases.
Introduction
Disease-specific ages of onset are core features of many neurological disorders, ranging from late-onset neurodegenerative diseases such as Alzheimer's and Parkinson's diseases (mean age at diagnosis~70 (Van Den Eeden et al., 2003) and~80 years (Nussbaum and Ellis, 2003) , respectively) to earlier onset psychiatric disorders such as schizophrenia and bipolar disorder (average onset~25 years) (Tsuang and Tohen, 2002) . The mechanism(s) underlying age thresholds and the factors that contribute to individual variability in ages of onset within diseases are largely unknown. Studies have predominantly focused on contrasting disease brains with chronologically age-matched controls, a strategy that may be incomplete, as it is becoming increasingly evident that normal aging rates are an integral aspect and modulator of disease onset and progression. Evidence for this comes from the sheer prevalence of diseases with increasing age, such as Alzheimer's disease (AD), which increases exponentially from age 75 upward reaching nearly 45% by age 95 (Nussbaum and Ellis, 2003) . Also, animal models of extended longevity show corresponding delay of age-related diseases, including neurological diseases. For example, in both C. elegans and mice lifespan extension via reduction of insulin/insulin growth factor signaling resulted in delayed proteotoxicity in AD models (Cohen et al., 2006 (Cohen et al., , 2009 . Additionally, potential life extension by caloric restriction in primate models has demonstrated delayed brain atrophy (Colman et al., 2009 ) and Aβ deposition (Qin et al., 2006) , and improved functional outcomes in the context of modeled Parkinson's disease (PD) (Maswood et al., 2004) . Similarly, rodent studies link inflammation, insulin resistance, and their treatment with Alzheimer's disease pathology burden (Jiang et al., 2008; Yan et al., 2003) . Lastly, human genetic and environmental risk factors associated with normal cognitive decline also often associate with agegated neurological diseases. For example, the APOE4 allele and BDNF val66met alleles associate both with accelerated rates of normal cognitive decline (reviewed in Deary et al. (2004) ) and earlier onset of AD and PD (Feher et al., 2009; Li et al., 2004) and epidemiological studies have shown Neurobiology of Disease 41 (2011) 279-290 
